Press releasePRNewswire
Carisma Therapeutics
CARM · NASDAQ
$0.0005+$0.0003 (+150.00%)TodayMarket closed ·
Prev close $0.0002
About CARM
- Employees
- 46
- Headquarters
- PHILADELPHIA, Pennsylvania
- Listed
- Feb 6, 2014
- Sector
- Health Care
- Industry
- Biotechnology
- Website
- sesenbio.com
CARM key statistics
- Market cap
- 8.37K
- Price-earnings ratio
- 0.00
- Dividend yield
- —
- Average volume
- 3.49K
- Volume
- 1.33K
- Open price
- $0.0005
- High today
- $0.0005
- Low today
- $0.0005
- 52 Week high
- $0.10
- 52 Week low
- $0.0001
Carisma Therapeutics (CARM) at a glance
Carisma Therapeutics (CARM) last traded at $0.0005, with a market cap of 8.37K and a price-to-earnings ratio of 0.00.
Volume so far is 1.33K shares, below the average of 3.49K shares a day.
Over the past year Carisma Therapeutics has ranged from $0.0001 to $0.10, and now sits 0% of the way up that range.
Carisma Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q3 FY25 it reported $1.07 per share against an estimate of -$0.1224.
CARM earnings
Earnings per share, reported against the analyst estimate
Beat the estimate in 3 of the last 8 quarters, by 331.0% on average.
- Q4 FY23: reported -$0.52 per share against an estimate of -$0.5636
- Q1 FY24: reported -$0.46 per share against an estimate of -$0.4412
- Q2 FY24: reported -$0.27 per share against an estimate of -$0.3035
- Q3 FY24: reported -$0.31 per share against an estimate of -$0.2652
- Q4 FY24: reported -$0.42 per share against an estimate of -$0.1658
- Q1 FY25: reported -$0.22 per share against an estimate of -$0.1224
- Q2 FY25: reported -$0.23 per share against an estimate of -$0.0918
- Q3 FY25: reported $1.07 per share against an estimate of -$0.1224
CARM news
- Avi Kapoor
Dow Surges 150 Points; US Consumer Sentiment Edges Lower
- Avi Kapoor
Dow Tumbles Over 1%; Nio Shares Edge Lower After Q2 Results
- Avi Kapoor
Nasdaq Down 1%; Signet Jewelers Earnings Top Views
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of Shareholders
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: TURN, HLGN, CARM, and GNTY
- Press releasePRNewswire
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE
Similar companies
Companies in the same industry as Carisma Therapeutics
Most active stocks
Highest trading volume today
- EARIEntertainment Arts Research$0.0003−16.67%
- SEIISharing Economy International$0.0004+100.00%
- NWGLCL Workshop Group$0.1522+27.90%
- TMSHTrans Global Assets$0.0002+0.00%
- AEFIAmerican EcoFuels$0.0007+0.00%
- CBDW1606$0.0002+0.00%
- FITYFifty 1 Labs$0.0001−66.67%
- PRSOPeraso$0.5914+54.13%
- SDSTStardust Power$0.02−23.66%
- SHFSSHF Holdings$0.0899−4.36%
- FRTTFort Technology$0.7121+32.63%
- CBDLCBD Life Sciences$0.0002−25.00%
Newly listed
Companies that went public in the past six weeks
- TCXBTCGX Acquisition Corp. II$10.56+1.54%
- CTYCITY THERAPEUTICS$20.83−2.94%
- IAMIambic Therapeutics$16.01−2.02%
- AMROAmaero$5.68+1.25%
- FLSCFrazier Life Sciences Acquisition Corp. II$10.28−0.10%
- TRXBTRex Bio$14.44−2.43%
- RTSNRetension Pharmaceuticals$16.18−0.92%
- PAXGUPine Tree Acquisition$9.98+0.00%
- PORTUSouthport Acquisition Corp. IIListed Oct 1, 2026
- CHWMChilwa Minerals$5.18+3.39%
- ACCVAccelevation Holdings$12.31−1.44%
- RZAIROZE AI$10.28+1.28%
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.